Ruthvik P. Avvari

Ruthvik P. Avvari

Auto-generated profile, based on publicly available information

Ruthvik P. Avvari

Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Science Advances
Verified
Journal Article
Open access
MAMahmoud S. Alghamri
Mahmoud S. Alghamri
BMBrandon L. McClellan
Brandon L. McClellan
RARuthvik P. Avvari
Ruthvik P. Avvari
RTRohit Thalla
Rohit Thalla
SCStephen Carney
Stephen Carney
MCMaria G. Castro
Maria G. Castro
Mutant isocitrate-dehydrogenase 1 ( mIDH1 ) synthesizes the oncometabolite 2-hydroxyglutarate (2HG), which elicits epigenetic reprogramming of the glioma cells’ transcriptome by inhibiting DNA and histone demethylases. We show that the efficacy of immune-stimulatory gene therapy (TK/Flt3L) is enhanced in mIDH1 gliomas, due to the reprogramming of the myeloid cells’ compartment infiltrating the tumor microenvironment (TME). We uncovered that the immature myeloid cells infiltrating the mIDH1 TME are mainly nonsuppressive neutrophils and preneutrophils. Myeloid cell reprogramming was triggered by granulocyte colony-stimulating factor (G-CSF) secreted by mIDH1 glioma stem/progenitor-like cells. Blocking G-CSF in mIDH1 glioma–bearing mice restores the inhibitory potential of the tumor-infiltrating myeloid cells, accelerating tumor progression. We demonstrate that G-CSF reprograms bone marrow granulopoiesis, resulting in noninhibitory myeloid cells within mIDH1 glioma TME and enhancing the efficacy of immune-stimulatory gene therapy.